Dahse, R. and Driemel, O. and Schwarz, S. and Dahse, J. and Kromeyer-Hauschild, K. and Berndt, A. and Kosmehl, H. (2009) Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. BRITISH JOURNAL OF CANCER, 100 (4). pp. 623-625. ISSN 0007-0920,
Full text not available from this repository. (Request a copy)Abstract
Activating mutations within the epidermal growth factor (EGFR) tyrosine kinase domain identify non-small cell lung cancer patients with improved clinical response to tyrosine kinase inhibitor therapy. Recently, we identified two EGFR mutations in a cohort of 25 salivary gland carcinomas (SGCs) by screening the tumour samples for the both most common hotspot mutations in exons 19 and 21 by allele-specific PCR. Here, we present a comprehensive sequencing analysis of the entire critical EGFR tyrosine kinase domain in 65 SGC of the main histopathological types. We found EGFR mutations in the tyrosine kinase domain to be a rare event in SGCs. No additional mutations other than the two known exon 19 deletions (c.2235_2249del15) in a mucoepidermoid carcinoma and an adenoid cystic carcinoma have been detected. Other putative predictive markers for EGFR-targeted therapy in SGCs might be relevant and should be investigated.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CELL LUNG-CANCER; PHASE-II TRIAL; EGFR MUTATIONS; GEFITINIB; ERLOTINIB; RECURRENT; THERAPY; EXON-19; NECK; GENE; epidermal growth factor receptor; mutation screening; salivary gland carcinomas; targeted therapy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Mund-, Kiefer- und Gesichtschirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 05 Oct 2020 09:50 |
| Last Modified: | 05 Oct 2020 09:50 |
| URI: | https://pred.uni-regensburg.de/id/eprint/29470 |
Actions (login required)
 |
View Item |
